secwatch.observer — SEC 8-K summary
======================================

Issuer:     USANA HEALTH SCIENCES INC (USNA)
CIK:        0000896264
Form:       8-K
Filed at:   2021-09-16T23:59:59+00:00
Accession:  0001157523-21-001149
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

USANA pre-announces Q3 net sales $265-$270M (down ~10% YoY); cuts FY2021 guidance
--------------------------------------------------------------------------------

- Preliminary Q3 EPS $1.28-$1.33 vs $1.44 prior year; net sales $265-$270M vs $299M.
- FY2021 guidance lowered: net sales $1.18-$1.20B (prev $1.24-$1.28B); EPS $5.80-$6.00 (prev $6.15-$6.50).
- CEO cites COVID disruptions, lockdowns, postponed events, and delayed product launches as headwinds.
- Board increases share repurchase authorization to $150M (includes $14M remaining).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/896264/000115752321001149/0001157523-21-001149-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/896264/000115752321001149/a52493306.htm
  HTML page:      https://secwatch.observer/filing/0001157523-21-001149

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer